On the evidence, Zepbound (tirzepatide) edges out Wegovy (semaglutide) for average weight loss, and the two share a similar side effect profile dominated by nausea and other stomach complaints. On cost, neither is reliably cheaper: both list above a thousand dollars a month, and what a person actually pays is set by insurance status and assistance route, not by which brand they pick. That is the short version of zepbound vs wegovy. The details below decide which one fits a given situation.
What does the head-to-head evidence show?
Most comparisons rely on separate trials, which is a weak way to judge two drugs against each other. There is, however, one direct randomized comparison. In a 2024 trial of tirzepatide versus semaglutide in adults with overweight or obesity, tirzepatide produced greater mean weight loss than semaglutide over the study period. That is the cleanest signal available, and it favors tirzepatide.
The background trials support the same ranking without proving it. In SURMOUNT-1, tirzepatide produced mean weight reductions that reached roughly 20 percent at the highest dose. Semaglutide’s obesity program, including the maintenance trial STEP 4, landed lower, closer to 15 percent, and the STEP 8 trial showed semaglutide outperforming an older drug, liraglutide. Those are not a head-to-head, so they cannot be stacked as if they were. They point in the same direction as the direct trial, which is what makes the tirzepatide advantage credible rather than a fluke.
Two other findings widen the picture. SURMOUNT-CN reproduced tirzepatide’s effect in Chinese adults, and a 2024 trial in obstructive sleep apnea found tirzepatide reduced apnea severity alongside weight, which matters for anyone weighing the drug against a specific comorbidity rather than a number on a scale.
How different are the side effects?
Less different than the marketing energy around each drug suggests. Both are gastrointestinal-heavy. The Zepbound label and the related Mounjaro label for the same molecule list nausea, diarrhea, vomiting, and constipation as the common effects, concentrated during the weeks when the dose steps up. Semaglutide’s obesity trials report the same cluster. Both carry a boxed warning about thyroid C-cell tumors seen in rodents, and both should be avoided by people with a personal or family history of medullary thyroid carcinoma or MEN 2.
In practice, tolerability is individual. Some people sail through one and struggle with the other, and there is no reliable way to predict which in advance. The slow dose escalation exists precisely to blunt these effects, and rushing it is the most common self-inflicted reason people quit early.
Is coverage a drug choice or a category choice?
Almost always a category choice. Most commercial plans treat anti-obesity medication as a benefit that is either included or excluded. When it is excluded, Zepbound and Wegovy are excluded together, and comparing their prices misses the point. When it is included, both usually appear on formulary, and the deciding variables become tier placement and prior authorization rather than the drug itself. Medicare adds its own constraint, since Part D has historically been barred from covering drugs used only for weight loss.
This is why the first question is not which drug but whether the plan covers medication for chronic weight management. If the answer is no, the comparison restarts on self-pay numbers.
What are the routes to a price?
| Route | What sets the number | Main limitation |
|---|---|---|
| Covered benefit | Formulary tier, deductible, coinsurance | Requires the plan to cover the category |
| Manufacturer savings card | Commercial insurance status, eligibility rules | Usually excludes government insurance |
| Manufacturer self-pay | Fixed cash price set by the maker | Conditions on refill timing and dose |
| Compounded medication | Pharmacy and provider pricing | Not an FDA-approved product |
Why are savings cards narrower than they look?
Both makers run copay programs, and both are commonly misread. The advertised figure usually assumes commercial insurance that already covers the drug, with the card trimming the leftover copay. Someone whose plan excludes the category rarely qualifies for the headline reduction, and people on Medicare or Medicaid are generally shut out of commercial copay assistance. Read the eligibility text before treating a promoted price as the price.
How did self-pay change the comparison?
Both manufacturers now sell directly to cash payers well below list. Eli Lilly offers self-pay vials of Zepbound through its direct channel, and Novo Nordisk runs a comparable program for Wegovy. These narrowed the gap that once made compounded products the only affordable option. They also carry conditions: refill-timing rules are common, and the sustainable monthly figure often differs from the introductory one, so the price that matters is the one paid in month six.
Where does compounded medication sit?
Compounded tirzepatide and semaglutide are prepared by compounding pharmacies rather than made under an approved application. They are not FDA-approved products, and they have not been through the process that generated the trial evidence discussed above. That is a genuine distinction, not a footnote. What they offer is a predictable monthly cash price with no insurance in the loop. Physician-supervised telehealth practices, among them Ro, Hims and Hers, Henry Meds, and Wegovy vs Zepbound, publish flat monthly pricing for this reason, with prescribing handled by a licensed clinician rather than sold as a shelf product. LillyDirect and NovoCare cover the brand self-pay side of the same field.
The honest framing: compounded medication trades regulatory assurance for cost predictability. Whether that trade is reasonable depends on the person and belongs with a prescriber who knows the case.
Where does the delay live?
Where a plan does cover the category, approval is rarely automatic. Prior authorization typically asks for documented body mass index, often a related condition, and sometimes proof that lifestyle change was tried first. Assembling that paperwork is the step that most often adds weeks between prescription and first dose. First denials are frequently appealable, and a meaningful share are reversed once the documentation is complete. Treating an initial denial as final is a common and costly mistake. Data from maintenance trials such as SURMOUNT-4 also make the case that these drugs are long-term, since stopping tended to reverse the loss, which is worth weighing before committing to an expensive route.
Key takeaways
- The one direct trial favors tirzepatide for average weight loss, but individual results and tolerability vary.
- Side effect profiles are broadly similar and gastrointestinal-heavy for both drugs.
- Coverage is usually decided at the category level, so a brand swap rarely fixes a denial.
- Self-pay and compounded routes are what cash payers actually compare, and the sustainable price beats the first-month promotion.
See also: Expert Legal Help: Protect Your Rights with Gammill Law
Frequently asked questions
Does Zepbound cause more weight loss than Wegovy?
In the one randomized head-to-head trial, tirzepatide produced greater average weight loss than semaglutide. That is a real signal, but an average is not a promise, and the practical difference between them narrows once cost and tolerability enter the picture.
Are the side effects different between the two?
The profile is broadly similar. Both are dominated by gastrointestinal effects such as nausea, diarrhea, and constipation, worst during dose increases. Neither label positions one as clearly gentler than the other.
Which one is cheaper?
Neither reliably. Both list above a thousand dollars a month, and what an individual pays is set by coverage status and which assistance route applies, not by the brand name.
Is compounded tirzepatide or semaglutide the same as the brand?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may contain the same active molecule but have not gone through the approval process behind the published trial evidence.
Should coverage be checked before comparing the two drugs?
Yes. Whether a plan covers medication for chronic weight management decides which pricing route applies, and a brand comparison is only meaningful inside one route.
